Impella devices have become an important option for temporary mechanical circulatory support (MCS) in the treatment of cardiogenic shock (CS) and high-risk percutaneous coronary interventions (PCI, Figure 1 ). In a recent issue of The American Journal of Cardiology , Pietro et al. present valuable insights into another vulnerable population, showing that Impella-supported high-risk PCI yields acceptable short-term outcomes in anatomically and clinically complex patients when surgery is not feasible ( Figure 2 ). While these results do not justify routine use in all cases, they strengthen the rationale for mechanical support in carefully selected patients. To define the role of Impella more precisely, rigorously designed randomized trials and well-structured registries remain essential.
Coronary angiography and percutaneous coronary intervention with impella support in acute myocardial infarction. (A) Baseline angiogram showing severe coronary obstruction (arrow) with Impella device in place (arrows). (B) Predilatation with plain old balloon angioplasty (POBA, arrows). (C) Post-POBA angiogram demonstrating partial restoration of coronary flow. (D) Deployment of coronary stent at the lesion site (arrows). (E) Final angiogram showing good stent expansion and restoration of coronary blood flow under Impella support.
Conceptual framework of Impella support during high-risk PCI. Impella use improves short-term outcomes but is associated with increased risks, including bleeding, pulmonary edema and differential hypoxia, and vascular complications.
At present, no universally accepted definition of high-risk PCI exists. Pietro et al. applied a pragmatic framework requiring at least 1 clinical and 1 anatomical risk feature. Clinical risk factors included advanced age (>75 years), diabetes, left ventricular ejection fraction <35%, acute coronary syndrome, prior cardiac surgery, peripheral vascular disease, advanced chronic kidney disease (eGFR <30 ml/min/1.73 m²), chronic obstructive pulmonary disease, and severe valvular disease. Anatomical factors included unprotected left main disease, degenerated vein grafts, severely calcified lesions requiring atherectomy, last remaining conduit, or chronic total occlusion in multivessel disease.
Future studies should standardize high-risk PCI definitions, stratify risk using both clinical and anatomical parameters, and incorporate advanced tools such as residual SYNTAX score, plaque morphology, and ischemic burden quantification. Registries should capture detailed procedural information, including timing of Impella insertion, device type (2.5, CP, 5.0/5.5), and completeness of revascularization, to refine patient selection and optimize outcomes. Cost-effectiveness also warrants careful evaluation, as the high expense of Impella remains a major barrier to broader adoption.
The clinical impact of Impella in CS has been examined in a recent meta-analysis of 17 studies including 3,933 patients, which reported persistently high 30-day mortality of 47.8% despite support, with major bleeding (15.2%) and vascular complications (7.4%) as significant adverse events ( Figure 2 ). Importantly, use of the Impella CP or 5.0/5.5, early initiation prior to revascularization, and absence of cardiac arrest were associated with improved survival and fewer complications. Nevertheless, managing CS complicating acute myocardial infarction remains a formidable challenge, with mortality still ranging from 40% to 50%. , The IABP-SHOCK II trial established that intra-aortic balloon pump therapy does not improve survival, yet the use of Impella and venoarterial extracorporeal membrane oxygenation (VA-ECMO) has expanded rapidly despite limited randomized evidence. ,,
In the largest European claims-based cohort of acute myocardial infarction, outcomes, complications, and healthcare costs were compared between Impella and VA-ECMO. Although mortality, complication rates, and resource use were high in both groups, VA-ECMO was associated with higher in-hospital mortality, more adverse events, longer length of stay, and greater hospitalization costs than Impella. These findings, though limited by residual confounding, underscore the urgent need for prospective studies to guide device selection and optimize outcomes.
Bleeding remains a critical concern during Impella support ( Figure 2 ), partly due to acquired von Willebrand syndrome (AVWS). AVWS, caused by shear-stress–mediated proteolysis of high-molecular-weight multimers of von Willebrand factor by ADAMTS13, has been linked to lower short-term survival in patients receiving temporary MCS. , Bleeding complications during Impella use were associated with AVWS, and aPTT monitoring alone proved insufficient to mitigate this risk. Development of more targeted anticoagulation strategies and standardized assays for high-molecular-weight multimers may help reduce bleeding events.
Pulmonary edema and differential hypoxia represent additional concerns in patients supported with VA-ECMO and Impella ( Figure 2 ). A retrospective study showed that, in patients with cardiopulmonary arrest, this combination was associated with a significantly increased risk of differential hypoxia requiring conversion to veno-arteriovenous ECMO, particularly beyond 96 hours. While Impella can alleviate pulmonary congestion, its concomitant use with VA-ECMO may amplify hypoxia risk, highlighting the importance of individualized multidisciplinary planning.
Ultimately, stabilizing patients prior to revascularization—including through guideline-directed medical therapy—enhances procedural safety and long-term outcomes. As MCS strategies continue to evolve, the balance between clinical efficacy, optimal patient selection, and economic sustainability will be critical to defining the role of Impella in both cardiogenic shock and high-risk PCI.
CRediT authorship contribution statement
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
